Trial
NCT01101594
A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Gilead Sciences
Collaborators
—
Condition
Multiple Myeloma
Intervention
hLL1-DOX (the doxorubicin conjugate of milatuzumab)
Why stopped
Study was terminated due to lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-08-16